

IPA Assam State Branch

AICTE sponsored four day workshop.

The Indian Pharmaceutical Association (IPA), Assam State Branch in association with the Dept. of Pharm. Sciences, Dibrugarh University organised a four days AICTE sponsored workshop on Herbal Drug Technology (Utilization of medicinal plants of NE India) from 9th to 12th Feb. 2010 in the Dept. of Pharm Sciences, Dibrugarh University.

The workshop was inaugurated by the Vice chancellor, Dibrugarh university and the keynote address was delivered by Dr. Dipak Chetia, President IPA Assam State branch, and H.K. Sharma Hon. Secy., IPA



'Inaugural Session' Assam State Branch welcomed participants & conveyed Thanks.

Resource persons from various organizations viz. Drug control authority, Govt. of Assam; Govt. Ayurvedic College, Assam; Anchrom, Mumbai; Lab India, Kolkata; North East Institute of Science and Technology, Jorhat; Rain Forest Research Institute; Jorhat, Regional Medical Research Centre (NE Region), presented their



Technical Session

deliberations in the workshop. The participants were also taken for a visit to pharmaceutical industry namely Quality Pharma Ltd., Dibrugarh.

IPA Rajkot Branch Inter Pharma League 2010

Indian Pharmaceutical Association (IPA) Rajkot Branch in association with S. J. Thakkar Pharmacy college, Rajkot organized **Inter Pharma League 2010 (IPA - 2010)** during 10th to 13th February 2010 among



different Pharmacy Colleges of Saurashtra region.

IPA- 2010 arranged different competition like sports viz. cricket, volleyball, chess, carom, Arts viz. Matka, mehndi, rangoli, salad & cartoon sketch, cultural event viz. dance, Drama Ras garba, Pharmaquiz.

There were 550 students of 13 different pharmacy college of Saurashtra region have participated. All winners' students and team received a shield, certificate and prize.

The program was inaugurated with Sarswati Vandana and deep pragtya by Honorable Dr. Kamleshbhai Joshipura, Vice - chancellor of Saurashtra University, Rajkot followed by welcome speech by Dr. Manish A. Rachchh, I/c Principal of the college as well as secretary of IPA - Rajkot branch.

DRUG APPROVALS

www.drugs.com

Asclera (polidocanol) Injection
Company: Chemische Fabrik Kreussler & Co.
Date of Approval: March 30, 2010
Treatment for: **Varicose Vein**
Asclera (polidocanol) is a sclerosing agent used for the treatment of varicose veins.

Zyclara (imiquimod) Cream
Company: Graceway Pharmaceuticals, LLC
Date of Approval: March 25, 2010
Treatment for: **Actinic Keratosis**
Zyclara (imiquimod) is an immune response modifier indicated for the topical treatment of actinic keratoses.

Carbaglu (carglumic acid) Tablets
Company: Orphan Europe
Date of Approval: March 18, 2010
Treatment for: **NAGS Deficiency Hyperammonemia**
Carbaglu (carglumic acid) is a carbamoyl phosphate synthetase 1 (CPS 1) activator indicated for the treatment of hyperammonemia due to the deficiency of the hepatic enzyme N-acetylglutamate synthase (NAGS).

Silenor (doxepin) Tablets
Company: Somaxon Pharmaceuticals, Inc.
Date of Approval: March 17, 2010
Treatment for: **Insomnia**
Silenor (doxepin) is a low-dose oral tablet formulation of the H1 receptor antagonist doxepin indicated for the treatment of insomnia characterized by difficulties with sleep maintenance.

Exalgo (hydromorphone) Extended Release Tablets
Company: Covidien
Date of Approval: March 1, 2010

Treatment for: Pain

Exalgo (hydromorphone) is a once-a-day extended release opioid formulation for the management of moderate to severe pain in opioid-tolerant patients requiring continuous, around-the-clock opioid analgesia for an extended period of time.

VPRIV (velaglucerase alfa) for Injection
Company: Shire plc
Date of Approval: February 26, 2010
Treatment for: **Gaucher Disease**
VPRIV (velaglucerase alfa) is a hydrolytic lysosomal glucocerebrosidase-specific enzyme indicated for long-term enzyme replacement therapy for pediatric and adult patients with Type 1 Gaucher disease.

Prevnar 13 (pneumococcal 13-valent conjugate vaccine)
Company: Wyeth Pharmaceuticals Inc.
Date of Approval: February 24, 2010
Treatment for: **Pneumococcal Disease Prophylaxis**
Prevnar 13 (pneumococcal 13-valent conjugate vaccine) is a vaccine indicated for active immunization against invasive pneumococcal disease in infants and young children.

Cayston (aztreonam lysine) Inhalation Solution
Company: Gilead Sciences, Inc.
Date of Approval: February 22, 2010
Treatment for: **Pneumonia with Cystic Fibrosis**
Cayston (aztreonam lysine for inhalation) is an inhaled anti-pseudomonas therapy for people with cystic fibrosis (CF) who have pulmonary Pseudomonas aeruginosa infection.